Introduction
============

An estimated 800,000 people live with dementia in the UK, at a cost of £23 billion annually \[[@B1]\]. By 2021 the number of people with dementia is expected to rise to over 1 million with an associated increase in costs. There has been somewhat of an attitude shift towards dementia of late - after decades of relative obscurity relative to diseases such as cancer and cardiovascular disease, dementia is now firmly on the national health and social care policy agenda of many high income countries.

Dementia policy in England
==========================

Living Well with Dementia, A National Dementia Strategy (NDS) for England was published in 2009 \[[@B2]\], setting out a vision for the transformation of dementia services following reports by the National Audit Office \[[@B3]\] and the Public Accounts Committee \[[@B4]\] concluding that dementia services provided poor value for money and that national policy had not prioritised dementia sufficiently. The same year saw the publication of the Banerjee report \[[@B5]\], \'Time for Action\'. The report highlighted the problem use of antipsychotics in those with dementia and led to the reduced use of antipsychotic medication being included in the top five priorities in the updated implementation plan for the NDS as well as good quality early diagnosis and intervention for all, improved quality of care in hospitals, living well with dementia in care homes and support for carers. As part of the focus on antipsychotics, \'The Right Prescription: a call to action on the use of antipsychotics\', a joint initiative between the Dementia Action Alliance and the National Health Service (NHS) Institute for Innovation and Improvement to tackle the problem of antipsychotic prescribing in dementia, was launched in 2011 and is ongoing \[[@B6]\]. This initiative will ensure that every person with dementia on an antipsychotic will have a clinical review of their treatment. In July 2012 the results of a national audit showed a 50% reduction in the prescribing of antipsychotics in dementia in England between 2008 and 2011, which is encouraging, although regional variations do remain \[[@B7]\].

In March 2012 the UK Prime Minister (PM), David Cameron, launched the latest drive to improve the care of those with dementia by 2015, announcing three key commitments: improvements in health and care, creation of dementia friendly communities and better research \[[@B8]\]. The PM challenge will build on the progress of the NDS but aims to \'push further and faster to improve the quality of life for people living with dementia, their families and carers\'. Among the plans was a more than doubling of the funding for research to over £66 million by 2015. The implementation plan for the PM challenge is now under way with working groups established to oversee each strand of the challenge with regular progress feedback to the PM\'s office.

Several reports have highlighted the poor care of patients with dementia in hospitals, the latest of which, the National Dementia Audit run by the Royal College of Psychiatrists in 2011, asked for significant improvements to be made to the care of inpatients with dementia \[[@B9]\]. 2012 also saw the launch of the dementia Commissioning for Quality and Innovation (CQUIN) payment framework, which rewards the identification of cognitive impairment in hospital inpatients aged 75 years and over \[[@B10]\]. This framework aims to drive up diagnosis rates of dementia, currently standing at 42%, improve inpatient services for those admitted with dementia by ensuring the diagnosis is recorded and to identify potentially reversible causes of cognitive impairment in the elderly, such as delirium and depression. The need to improve diagnosis rates and reduce regional variation has also been highlighted by the an All-Party Parliamentary Group report on dementia in July 2012 \[[@B11]\].

Dementia is a high level priority in the 2012/13 NHS operating framework, the document setting out the national priorities and strategy for the NHS \[[@B12]\]. Dementia also currently has a placeholder on the 2012/13 NHS outcomes framework, a set of indicators that will be used to hold the Clinical Commissioning Groups accountable to the NHS commissioning Board on outcomes \[[@B13]\].

International picture
=====================

Internationally, dementia is being championed across the world and several countries now have national dementia plans that can be accessed on the Alzheimer Europe \[[@B14]\] and Alzheimer\'s Disease International (ADI) \[[@B15]\] web-sites. Common themes in the strategies include early diagnosis, awareness raising, quality care, staff training, and research into prevention and better management of the disorder pharmacologically, behaviourally and socially. 2012 saw the launch of the first US national Alzheimer plan, with a number of goals, including the ambition to \'prevent and effectively treat Alzheimer\'s disease by 2025\' \[[@B16]\].

In April 2012 a joint report was launched by the World Health Organisation (WHO) and ADI - \'Dementia: a Public Health Priority\' - calling for raised awareness and governmental action globally \[[@B17]\]. It reported that, currently, 58% of all those with dementia live in low and middle income countries where the majority of dementia care is currently provided by extended families, with this figure projected to rise to 71% by 2050 given current population trends. The WHO advice to low and middle income countries, whose efforts have tended to centre on the prevention of communicable diseases, with a lack of specific dementia plans to date, is to focus on capacity building, including infrastructure and workforce training across the health and social care sector to enable a response to the dementia challenge. The report suggests dementia can be incorporated into older people or mental health national policies for these countries.

Partnership working
===================

Non-governmental organisations such as the Alzheimer\'s Society (UK) \[[@B18]\], Alzheimer\'s Association (USA) \[[@B19]\] and ADI play a central role in shaping and supporting national and international policy, including national plans. In the UK, for example, the Alzheimer\'s Society has been integral to the development and implementation phase of the 2009 national plan \[[@B2]\] and is overseeing the dementia friendly communities strand of the recent PM dementia challenge \[[@B8]\]. Equally, France Alzheimer is a major partner in the French national plan \[[@B20]\].

Furthermore, collaboration between public bodies and the commercial sector through data sharing and the setting of common research priorities is increasingly being recognised as a means of maximising opportunities, such as the identification of drug targets and novel biomarkers allowing for early intervention and prevention. The ministerial advisory group on dementia research in the UK has highlighted the need for cross-sector working in dementia, which will be addressed as part of a joint initiative between the Medical Research Council and the Association of the British Pharmaceutical Industry looking at a partnership working across a number of disease areas \[[@B21]\]. Most recently, David Cameron spoke about plans developed as part of the \'Strategy for UK Life Sciences\' \[[@B22]\] to share anonymised NHS patient data with universities and industry for the promotion of life sciences innovation, including in the field of dementia \[[@B23]\].

Conclusion
==========

There is a real sense that dementia\'s time is here in terms of priorities and is finally being recognised as a matter of national priority with commitment from governments across the world. It is now imperative that this momentum is seized upon to deliver on strategies to improve the lives of people with dementia and their carers.
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